Aznar JA - Search Results

1

Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain.

Batlle J, Villar A, Liras A, Alonso C, Altisent C, Brito D, Moreno M, Lucía F, Sedano C, Prieto M, Calvente N, Aznar JA, Jiménez V, Soriano V, Martorell JR, Iruín G, Bergua JM, Aguilar C. Batlle J, et al. Among authors: aznar ja. Blood Coagul Fibrinolysis. 2008 Jul;19(5):333-40. doi: 10.1097/MBC.0b013e328300c814. Blood Coagul Fibrinolysis. 2008. PMID: 18600079 Review.

2

Emerging viral infections‑-a potential threat for blood supply in the 21st century.

de Mendoza C, Altisent C, Aznar JA, Batlle J, Soriano V. de Mendoza C, et al. Among authors: aznar ja. AIDS Rev. 2012 Oct-Dec;14(4):279-89. AIDS Rev. 2012. PMID: 23258302 Review.

3

Markers of coagulation and platelet activation during percutaneous mitral valvuloplasty.

Fernández MA, Villa P, España F, Aznar J, Rincón de Arellano A, Cebolla R. Fernández MA, et al. Blood Coagul Fibrinolysis. 1998 Oct;9(7):581-5. doi: 10.1097/00001721-199810000-00003. Blood Coagul Fibrinolysis. 1998. PMID: 9863705

4

Lipoprotein(a) levels and isoforms and fibrinolytic activity in postmenopause--influence of hormone replacement therapy.

Estellés A, Cano A, Falcó C, España F, Gilabert J, Grancha S, Aznar J. Estellés A, et al. Thromb Haemost. 1999 Jan;81(1):104-10. Thromb Haemost. 1999. PMID: 10348700

5

The principal results of the International Immune Tolerance Study: a randomized dose comparison.

Hay CR, DiMichele DM; International Immune Tolerance Study. Hay CR, et al. Blood. 2012 Feb 9;119(6):1335-44. doi: 10.1182/blood-2011-08-369132. Epub 2011 Nov 18. Blood. 2012. PMID: 22101900 Free article. Clinical Trial.

6

Modified test for activated protein C resistance.

Jorquera JI, Montoro JM, Fernández MA, Aznar JA, Aznar J. Jorquera JI, et al. Among authors: aznar j, aznar ja. Lancet. 1994 Oct 22;344(8930):1162-3. doi: 10.1016/s0140-6736(94)90673-4. Lancet. 1994. PMID: 7864945 No abstract available.

7

Evaluation of an automated method for the quantification of von Willebrand factor antigen. Its application in the study of vascular dysfunction.

Villa P, Iborra J, Serra J, Gilsanz A, Casaña P, Aznar JA, Aznar J. Villa P, et al. Among authors: aznar j, aznar ja. Haematologica. 2001 Nov;86(11):1180-5. Haematologica. 2001. PMID: 11694404

8

Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype.

Estellés A, Dalmau J, Falcó C, Berbel O, Castelló R, España F, Aznar J. Estellés A, et al. Thromb Haemost. 2001 Aug;86(2):647-52. Thromb Haemost. 2001. PMID: 11522017

9

Evidence of activation of the protein C pathway during acute vascular damage induced by Mediterranean spotted fever.

Vicente V, España F, Tabernero D, Estellés A, Aznar J, Hendl S, Griffin JH. Vicente V, et al. Blood. 1991 Jul 15;78(2):416-22. Blood. 1991. PMID: 1648982 Free article.

10

Studies on the functionality of newly synthesized fibrinogen after treatment of acute myocardial infarction with streptokinase, increase in the rate of fibrinopeptide release.

Reganon E, Vila V, Aznar J, Lacueva V, Martinez V, Ruano M. Reganon E, et al. Thromb Haemost. 1993 Dec 20;70(6):978-83. Thromb Haemost. 1993. PMID: 8165621 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

360 results

Search Page